Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies

Rhea-AI Summary

AVITA Medical (NASDAQ: RCEL) presented data from 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, including the first surgeon-reported integrated use of RECELL, PermeaDerm, and Cohealyx in single care pathways.

Initial histological findings from PermeaDerm and Cohealyx trials showed early blood vessel growth and organized tissue formation without increased inflammation. RECELL evidence across comparative studies and registries indicated smaller donor sites, similar or faster healing, fewer complications, and substantial hospital-stay reductions (nearly 16 days shorter in one older-patient study; ~33% less time in hospital in another registry analysis).

Positive

• 19 abstracts presented at Boswick Symposium
• First surgeon-reported integrated use of RECELL, PermeaDerm, Cohealyx
• PermeaDerm histology: early blood vessel growth without increased inflammation
• Cohealyx histology: cellular infiltration and early vessel formation within two weeks
• RECELL associated with nearly 16-day shorter hospital stays in older patients
• RECELL registry: ~33% less inpatient time for deep partial-thickness burns

Negative

• PermeaDerm and Cohealyx results are from initial or ongoing trials with full results pending in 2026
• Some presented data are single-patient or early-case reports, limiting generalizability

Key Figures

Scientific abstracts: 19 abstracts Podium presentations: 14 podium presentations Comparative studies count: 27 peer-reviewed studies +5 more

8 metrics

Scientific abstracts 19 abstracts Data presented at 2026 Boswick Burn & Wound Symposium

Podium presentations 14 podium presentations AVITA-related presentations at Boswick Symposium

Comparative studies count 27 peer-reviewed studies Systematic review of RECELL outcomes vs conventional closure

Elderly burn stay reduction nearly 16 days shorter RECELL plus grafting vs standard grafting in patients ≥65

Hospital time reduction about one-third less time RECELL vs traditional grafting for deep partial-thickness burns

Cohealyx readiness timeline within two weeks Time to wound readiness for grafting in initial Cohealyx I case

Integrated case count two challenging cases First surgeon-reported integrated use of all three technologies

Older patient threshold 65 and older Burn patient age group in RECELL real-world study

Market Reality Check

Price: $4.44 Vol: Volume 322,349 is 1.37x t...

normal vol

$4.44 Last Close

Volume Volume 322,349 is 1.37x the 20-day average of 235,367, indicating elevated interest ahead of this update. normal

Technical At $4.44, shares trade below the 200-day MA of $5.28, despite today’s positive clinical news.

Peers on Argus

Sector peers show mixed moves: PROF +3.24%, ICAD +3.48%, LNSR +1.46%, while RPID...

1 Up

Sector peers show mixed moves: PROF +3.24%, ICAD +3.48%, LNSR +1.46%, while RPID -6.15% and SERA -6.09%. Momentum scanner flags only BDMD at +5.35999983549118% with no news, supporting a stock-specific reaction.

Historical Context

5 past events · Latest: Jan 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 13	Preliminary results & outlook	Positive	-3.5%	Outlined 2025 revenue growth, 2026 guidance, and new $60M credit facility.
Jan 05	Board changes	Neutral	+0.0%	Announced director appointment and long-serving chairman’s retirement.
Dec 18	Conference presentation	Positive	+3.0%	Confirmed J.P. Morgan Healthcare Conference presentation and webcast access.
Nov 24	Conference appearance	Neutral	+0.0%	Piper Sandler conference participation and investor meeting availability.
Nov 09	Investor webinar	Neutral	+5.3%	Planned investor webinar to review Q3 2025 results and take Q&A.

Pattern Detected

Recent AVITA news has drawn mixed reactions, with some positive operational updates met by selling and neutral items occasionally attracting buying.

Recent Company History

Over the last few months, AVITA has focused on investor outreach and financial visibility, including conference appearances on Nov 24, 2025 and Dec 4, 2025, plus an investor webinar on Nov 12, 2025. A key pre-J.P. Morgan update on Jan 13, 2026 detailed 2025 revenue growth, new credit capacity, and 2026 guidance but saw a negative price reaction. Today’s symposium data extends that trajectory by emphasizing clinical usage and outcomes for RECELL, PermeaDerm, and Cohealyx.

Market Pulse Summary

This announcement highlights expanded clinical evidence for AVITA’s technologies, including RECELL, ...

Analysis

This announcement highlights expanded clinical evidence for AVITA’s technologies, including RECELL, PermeaDerm, and Cohealyx, across 19 abstracts and 14 podium talks. Data from elderly burn patients and deep partial-thickness burns emphasize shorter hospital stays and fewer graft failures. Recent history, including 2025 revenue updates and new credit capacity, shows concurrent financial and clinical progress. Investors may watch for full 2026 trial readouts and how real-world utilization trends evolve.

Key Terms

histological

1 terms

histological medical

"investigators described their center’s experience and histological results from the ongoing PermeaDerm I clinical trial"

Relating to the microscopic study of tissues, histological describes how cells and tissue structures look when viewed under a microscope. For investors, histological results can confirm whether a drug or medical procedure actually changes disease tissue or causes harm — like inspecting the weave of fabric to spot repairs or tears — and those findings often influence trial outcomes, regulatory decisions, and commercial prospects.

AI-generated analysis. Not financial advice.

• First surgeon-reported case using RECELL^®, PermeaDerm^®, and Cohealyx^™ together in a single care pathway
  
  
• New clinical and tissue-level data on PermeaDerm and Cohealyx highlight wound bed preparation and readiness for closure
  
  
• RECELL analyses show consistent trends in healing, reduced complications, and shorter hospital stays across studies and real-world registry data
  
  

VALENCIA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced data from 19 scientific abstracts, including 14 podium presentations, at the 2026 Boswick Burn & Wound Symposium. The presentations include the first surgeon-reported integrated use of all three AVITA Medical technologies – RECELL, PermeaDerm, and Cohealyx – in individual patient cases, as well as clinical and tissue-level findings from separate studies evaluating PermeaDerm and Cohealyx.

Additional presentations at the meeting build on AVITA Medical’s established RECELL evidence base, offering synthesis and real-world insight across comparative studies, registries, and older compromised patient populations. Together, the data illustrate how surgeons are using RECELL to improve healing, reduce complications, and shorten hospital stays in burn and complex wound care.

First Surgeon-Reported Integrated Use of All Three AVITA Medical Technologies

One of the most notable presentations at the Boswick Symposium described the first surgeon-reported experience integrating RECELL, PermeaDerm, and Cohealyx, as illustrated through two challenging cases. In the two cases involving a young trauma patient and an elderly patient with a large full-thickness wound, surgeons used:

• PermeaDerm for wound coverage
• Cohealyx to help prepare the wound for closure, and
• RECELL (combined with skin grafting) for final healing
  
  

This approach reduced the need for frequent, painful dressing changes and avoided long-distance follow-up appointments. Authors noted that this type of integrated care may be especially important for rural and community hospitals with limited access to specialized burn services¹.

New Histological Findings Support PermeaDerm and Cohealyx

Investigators also presented initial findings from their participation in multicenter clinical trials evaluating PermeaDerm and Cohealyx; full study results are expected in 2026.

In one presentation, investigators described their center’s experience and histological results from the ongoing PermeaDerm I clinical trial for temporary wound coverage. Tissue findings showed that PermeaDerm supported early blood vessel growth and more organized tissue formation compared with donated human skin commonly used for temporary coverage. Importantly, this occurred without increased inflammation, which can interfere with healing, offering insight into how PermeaDerm may support more predictable wound bed preparation ahead of definitive closure².

In another presentation, investigators reported on a single patient experience and initial histological findings from the Cohealyx I clinical trial evaluating its ability to advance wound bed ​preparation and readiness for closure. In this initial case, tissue findings showed that Cohealyx supported cellular infiltration and early blood vessel formation within two weeks, allowing the wound to become ready for skin grafting without complication³.

Evidence Shows Healing and Utilization Benefits With RECELL

Building on previously reported RECELL findings, a comprehensive systematic review led by Dr. Anju Bakhshi Saraswat, was presented which included an examination of outcomes across 27 peer-reviewed studies drawn from a broader global evidence base. This examination compared RECELL-based treatment with conventional wound closure approaches, including split-thickness skin grafting⁴.

Across these comparative studies, RECELL use was associated with:

• Smaller donor sites
• Similar or faster healing times
• Improvements to pain and appearance outcomes, and
• More favorable health economic outcomes
  
  

Additional real-world and registry-based studies presented reinforced these findings. In a study of burn patients aged 65 and older, adding RECELL to standard skin grafting was associated with fewer graft failures and hospital stays that were nearly 16 days shorter among patients who survived to discharge⁵. In a separate national registry analysis, adults with deep partial-thickness burns treated with RECELL spent about one-third less time in the hospital than those treated with traditional grafting. These patients were also more likely to be discharged directly home⁶.

Together, the consistency of findings across comparative studies, real-world analyses, and higher-risk patient populations suggests that RECELL performs predictably in routine clinical practice, reinforcing its role as a foundational component of staged wound care strategies.

Practical, Surgeon-Led Approaches to Modern Burn Care

“Across these presentations, surgeons are demonstrating how staged use of our advanced wound care technologies, either independently or together, can improve healing while helping hospitals manage limited resources,” said Cary Vance, Interim CEO of AVITA Medical.

About AVITA Medical, Inc.

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

Sources / Abstract Citations (Boswick Burn & Wound Symposium 2026)

1. Mashruwala N. Integrated Use of Advanced Wound Care Technologies to Achieve Complex Wound Closure in a Rural Setting: A Case Series. Podium presentation, Boswick Burn & Wound Symposium 2026.
2. Deeter L, Prasai A, Bush K, et al. Histologic Evaluation of Biosynthetic Wound Matrix and Cadaveric Allograft Strategies for Wound Temporization. Podium presentation, Boswick Burn & Wound Symposium 2026
3. Castañón L, Trutter B, Matthews M. Early Histologic Evidence of Integration and Tissue Formation with a Bovine Dermal Collagen Matrix in Full-Thickness Wounds: First Patient Experience from a Multicenter Trial. QuickShot podium presentation, Boswick Burn & Wound Symposium 2026.
4. Saraswat AB, Holmes JH IV. Global Clinical Evidence Establishes Skin Cell Suspension Autograft as an Evidence-Based Approach in Wound Care. Podium presentation, Boswick Burn & Wound Symposium 2026.
5. Deeter L, Subramaniam J, Osborn S, et al. Skin Cell Suspension Autograft Reduces Graft Loss and Hospital Length of Stay in Medicare-Eligible Burn Patients: A Propensity-Matched Retrospective Cohort Analysis. Podium presentation, Boswick Burn & Wound Symposium 2026.
6. Schoen JE, Carter JE, Miles VP, Phillips B. Skin Cell Suspension Autograft Shortens Length of Stay by 36% in Deep Partial-Thickness Burns: Insights from a National Registry Analysis. Podium presentation, Boswick Burn & Wound Symposium 2026.
   
   

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “potential,” “project,” “target,” “will,” “would,” and similar words or expressions, and the use of future dates. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation: the conduct or outcome of pre-clinical or clinical (human) studies; industry market conditions; failure to obtain and/or maintain regulatory approvals and comply with applicable regulations; market reaction to growth or product initiatives; market penetration of our products; changes in the legal or regulatory environments; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company’s control. Any forward-looking statements made herein are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the “Risk Factors” section of the Company’s latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.

Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com | media@avitamedical.com

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

©2025 AVITA Medical. AVITA Medical®, Cohealyx®, RECELL®, RECELL GO®, and Spray-On Skin^TM Cells are trademarks of AVITA Medical. PermeaDerm® is a registered trademark owned by Stedical Scientific, Inc. All other trademarks are the properties of their respective owners.

FAQ

What did AVITA (RCEL) present at the 2026 Boswick Burn & Wound Symposium?

AVITA presented 19 abstracts, including the first surgeon-reported integrated use of RECELL, PermeaDerm, and Cohealyx and initial histological trial findings.

What clinical benefits were reported for RECELL in the Boswick presentations for RCEL?

RECELL was linked to smaller donor sites, similar or faster healing, fewer complications, and large inpatient stay reductions (e.g., nearly 16 days shorter in one study).

What did PermeaDerm histology show in AVITA trial reports at Boswick 2026?

Initial PermeaDerm histology showed early blood vessel growth and more organized tissue formation without increased inflammation.

How quickly did Cohealyx show tissue changes in the reported case for RCEL?

In the initial reported case, Cohealyx supported cellular infiltration and early blood vessel formation within two weeks, enabling readiness for grafting.

Are the PermeaDerm and Cohealyx trial results final for AVITA (RCEL)?

No; the presentations reported initial or ongoing trial findings and noted that full study results are expected in 2026.

What patient populations showed benefit with RECELL in the Boswick data for RCEL?

Benefits were reported across comparative studies, registries, and higher-risk groups, including burn patients aged 65 and older with fewer graft failures and shorter stays.